BioNexus Gene Lab Corp Common stock Capital Reinvestment Ratio
BioNexus Gene Lab Corp Common stock capital reinvestment ratio. BioNexus Gene Lab Corp Common stock (BGLC) has a Capital Reinvestment Ratio of 0.04x as of December 2022, meaning it reinvests 0% of its operating cash flow ($474.47K) in capital expenditures ($17.03K). Check cash flow reinvestment rate of BioNexus Gene Lab Corp Common stock to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of BioNexus Gene Lab Corp Common stock (2017–2022)
Capital reinvestment ratio of BioNexus Gene Lab Corp Common stock from 2017 to 2022. This chart tracks BioNexus Gene Lab Corp Common stock's Capital Reinvestment Ratio across 4 annual periods. Also explore net asset growth rate of BioNexus Gene Lab Corp Common stock to track the company's year-over-year net asset growth rate.
BioNexus Gene Lab Corp Common stock Capital Reinvestment Ratio by Year (2017–2022)
BioNexus Gene Lab Corp Common stock capital reinvestment ratio by year from 2017 to 2022. For the full cash flow conversion analysis, see BGLC cash flow metrics.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.10x | $544.03K | $54.17K | ▼ -71.2% |
| 2021 | 0.35x | $9.16K | $3.16K | ▼ -54.8% |
| 2020 | 0.76x | $552.68K | $421.62K | ▼ -13.4% |
| 2017 | 0.88x | $357.22K | $314.82K | — |